{"entity":{"id":"nct05712902","kind":"trial","name":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","aka":["WU-KONG6"],"tldr":"A phase 2 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, active and no longer recruiting.","summary":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) is a phase 2 interventional study registered as NCT05712902 by Dizal Pharmaceuticals, with 104 participants enrolled, started 2021-07-19 and due to reach its primary completion in 2022-10-17. Interventions recorded: Sunvozertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05712902","url":"https://clinicaltrials.gov/study/NCT05712902"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["sunvozertinib"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05712902-lancet-respir-med-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05712902","phase":"2","setting":"A Phase II, Single Arm, Multicenter Study to Evaluate Anti-tumor Activity, Safety, Tolerability and Pharmacokinetics of DZD9008 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation","sponsor":"Dizal Pharmaceuticals","started":"2021-07-19","startedType":"actual","enrolled":104,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05712902/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}],"paper":[{"id":"paper-nct05712902-lancet-respir-med-2024","kind":"paper","name":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial","route":"/key-papers/paper-nct05712902-lancet-respir-med-2024/"}]}}